{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=8", "query": { "intervention": "Placebo; placebo comparator condition", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 7764, "total_pages": 777, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T13:30:46.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04632940", "title": "Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Pamrevlumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "MALE", "summary": "6 Years to 11 Years · Male only" }, "enrollment_count": 73, "start_date": "2021-03-03", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04632940" }, { "nct_id": "NCT04259060", "title": "Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Hydroxocobalamin with Butyrate", "type": "DRUG" }, { "name": "Placebo with Butyrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joshua Korzenik", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2024-01", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 1, "location_summary": "Chestnut Hill, Massachusetts", "locations": [ { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04259060" }, { "nct_id": "NCT06570369", "title": "A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder", "Depression", "Healthy" ], "interventions": [ { "name": "SP-624", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sirtsei Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 26, "start_date": "2024-08-22", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 2, "location_summary": "Garden Grove, California • Lincoln, Nebraska", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06570369" }, { "nct_id": "NCT03829241", "title": "Randomized Trial of Adult Participants With Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Troriluzole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 881, "start_date": "2019-02-19", "completion_date": "2020-05-08", "has_results": true, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 53, "location_summary": "Little Rock, Arkansas • Colton, California • Encino, California + 48 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Colton", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829241" }, { "nct_id": "NCT05597241", "title": "Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "apimostinel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndeio Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2022-10-15", "completion_date": "2023-04-04", "has_results": false, "last_update_posted_date": "2023-04-11", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 1, "location_summary": "Rogers, Arkansas", "locations": [ { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597241" }, { "nct_id": "NCT05376150", "title": "A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "XEN1101 10 mg", "type": "DRUG" }, { "name": "XEN1101 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xenon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 168, "start_date": "2022-05-19", "completion_date": "2023-10-16", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 20, "location_summary": "Anaheim, California • Lafayette, California • Pico Rivera, California + 15 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lafayette", "state": "California" }, { "city": "Pico Rivera", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376150" }, { "nct_id": "NCT06227910", "title": "A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 396, "start_date": "2025-01-02", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 19, "location_summary": "La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Naples", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06227910" }, { "nct_id": "NCT00896324", "title": "Intellectual Impairment in Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cognitive Rehabilitation", "type": "BEHAVIORAL" }, { "name": "Active Neurofeedback Training", "type": "BEHAVIORAL" }, { "name": "Neurofeedback Training (placebo / Sham)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 50, "start_date": "2009-01-12", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896324" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 212, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 171 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" }, { "nct_id": "NCT02573870", "title": "Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Batefenterol + Fluticasone Furoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 63, "start_date": "2015-12-01", "completion_date": "2016-07-05", "has_results": true, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-13T13:30:46.921Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Gastonia", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573870" } ] }